Agios Pharmaceuticals, Inc. AGIO is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
Recently, Agios along with its partner Celgene announced that the FDA has granted approval to its lead candidate Idhifa for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. It is the first FDA-approved therapy for the given indication.
The company has several interesting candidates in its pipeline. Interesting candidates in cancer pipeline includes AG-120 (phase III study in front-line AML patients with an IDH1 mutant-positive advanced cholangiocarcinoma) and AG-881 (phase I study in IDHm positive glioma).
Agios’ earnings performance so far has been mixed with the company missing expectations in two of the last four reported quarters and beating in other two. Overall, the company has delivered an average positive beat of 0.34%.
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Agios Pharmaceuticals, Inc. Price and EPS Surprise | Agios Pharmaceuticals, Inc. Quote
Currently, Agios has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Loss Narrows: Agios posted narrower-than-expected loss in the third quarter of 2017. Our consensus called for a loss of $1.74 per share, and the company reported a loss of $1.59.
Revenues Beat: Revenues in the reported quarter also came above expectations. Agios posted revenues of approximately $11.4 million, compared to our consensus estimate of $11 million. The revenues increased 26.7% from year ago figure of $9 million.
Kay Stats: Research & development expenses were up 20.3% year over year to $72.9 million. General and administrative expenses increased 47% year over year to $17.5 million.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment